enGene Therapeutics reports preliminary FY2026 cash position of $245.8 million and announces Phase 2 LEGEND trial results for detalimogene. (Items: 2.02 Results of Operations and Financial Condition, 8.01 below is incorporated herein by reference, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)